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Abstract Bisphosphonates (BPs) slow bone loss by
reducing initiation of new basic multicellular units (BMUs).
Whether or not BPs simply prevent osteoclasts from initi
ating new BMUs that resorb bone or also reduce the amount
of bone they resorb at the BMU level is not clear. The goal of
this study was to determine the effects of BPs on three
morphological parameters of individual BMUs, resorption
depth (Rs.De), area (Rs.Ar), and width (Rs.Wi). After 1 year
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of treatment with vehicle (VEH), alendronate (ALN; 0.10,
0.20, or 1.00 mg/kg/day), or risedronate (RIS; 0.05, 0.10, or
0.50 mg/kg/day), resorption cavity morphology was asses
sed in vertebral trabecular bone of beagle dogs by histology.
Animals treated with ALN or RIS at the doses representing
those used to treat postmenopausal osteoporosis (0.20 and
0.10 mg/kg/day, respectively) had signiﬁcantly lower Rs.Ar
(-27%) and Rs.Wi (-17%), with no difference in Rs.De,
compared to VEH-treated controls. Low doses of ALN and
RIS did not affect any parameters, whereas higher doses
resulted in similar changes to those of the clinical dose. There
were no signiﬁcant differences in the resorption cavity
measures between RIS and ALN at any of the dose equiva
lents. These results highlight the importance of examining
parameters beyond erosion depth for assessment of resorp
tion parameters. Furthermore, these results suggest that in
addition to the well-known effects of BPs on reducing the
number of active BMUs, these drugs also reduce the activity
of osteoclasts at the individual BMU level at doses at and
above those used clinically for the treatment of postmeno
pausal osteoporosis.
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Bisphosphonates (BPs) are commonly used to prevent or
treat osteoporosis and other metabolic or oncogenic dis
eases that result in increased bone remodeling [1]. BPs act
by preventing osteoclast activation and causing apoptosis of
osteoclasts, resulting in the initiation of fewer active basic
multicellular units (BMUs) on bone surfaces [2]. Whether
or not BPs affect osteoclast activity at the individual BMU
level, i.e., the amount of bone that a team of osteoclasts

resorbs, is less clear. Suppressing osteoclast resorption at
the BMU level would represent an additional means
through which these drugs slow the rate of bone loss.
BMUs occur in vivo as three-dimensional units, yet they
are most often assessed in the laboratory as two-dimensional
structures via histomorphometry. Numerous techniques
have been used to assess morphological properties of the
BMU, and although the speciﬁc methods can differ, they all
focus on reconstructing BMUs in order to estimate various
parameters [3–6]. The most common parameter used to
determine BMU-level resorption activity is resorption depth
(Rs.De), deﬁned as the maximum distance from the cement
line of a BMU to the estimated original trabecular surface. In
a balanced remodeling system, this would be the same as
ﬁnal wall width, but when resorption and formation are not
balanced, wall width could be either greater or less than the
Rs.De. Studies examining BP treatment effects on Rs.De
have been equivocal, with most showing no difference
compared to untreated controls [3, 5, 7–9].
The goal of the current study was to determine the
effects of BPs on BMU-level bone resorption measures
beyond those of Rs.De. Speciﬁcally, we examined how
BPs affect resorption space area (Rs.Ar) and resorption
space width (Rs.Wi), along with the more commonly
assessed Rs.De. We hypothesized that BMU Rs.Ar would
be lower in animals treated with BPs compared to controls
as a result of lower Rs.De and Rs.Wi.

criteria: (1) resorption cavities that resided on a ﬂat, con
tinuous trabecular surface, (2) double calcein labels dis
played characteristic bow shaped curves meeting at the ends

Methods
Detailed methods concerning this experiment have been
previously published [10], and all procedures related to this
work were approved by the Indiana University School of
Medicine Institutional Animal Care and Use Committee
before the study initiation. Brieﬂy, 84 skeletally mature
female beagles were treated for 1 year with vehicle (VEH),
alendronate (ALN; 0.10, 0.20, or 1.00 mg/kg/day), or
risedronate (RIS; 0.05, 0.10, or 0.50 mg/kg/day). The
middle dose for each drug corresponds, on a mg/kg basis,
to the treatment dose for postmenopausal osteoporosis.
Before necropsy, most animals were injected with calcein
using a 2–12–2–5 labeling schedule; some animals (n = 3
per group) were labeled using a 2–5–2–5 schedule. The
shorter interlabel duration was due to a scheduling error.
Second lumbar vertebrae were embedded, undecalciﬁed, in
plastic, and 8-lm-thick unstained midsagittal sections were
prepared [10].
Sections were inspected, blinded to treatment, at 9250
magniﬁcation with an Olympus BH-2 microscope under
both ultraviolet and polarized light to view the calcein labels
and lamellae, respectively. For each animal, resorption
cavities were identiﬁed for analysis using the following

Fig. 1 Photomicrographs of a typical basic multicellular unit (BMU)
for which analysis of resorption parameters was conducted. a BMU
viewed with epiﬂuorescence to identify calcein labeling which
indicates active bone remodeling. b BMU viewed with polarized
light to identify the cement line which indicates the limit to erosion of
the remodeling unit. c Overlay of the two images used for
measurement of BMU morphology along with lines depicting how
the surface of the cavity was estimated for assessment of resorption
cavity width (Rs.Wi) and depth (Rs.De). Resorption cavity area
(Rs.Ar) was deﬁned as the space within the entire cavity, Images are
shown at original magniﬁcation 9250

(Fig. 1a), and (3) lamellae were clear and followed the same
contour as the calcein labels (Fig. 1b). Our choice to restrict
our analysis to ﬂat surfaces was to eliminate the likely var
iability associated with estimating the projected bone sur
face on BMUs located on curves. After identiﬁcation of
BMUs ﬁtting the above criteria, both ultraviolet and polar
ized light images of the region were taken by a PaxCam
camera (MIS Inc.).
Rs.Ar, Rs.Wi, and Rs.De were measured by ImageJ
software (NIH) with the calcein and ultraviolet light ima
ges overlaid (Fig. 1c). All measures were made by a single
observer who was blinded to the treatment. The perimeter
of the resorption cavity was outlined by using the end
points, determined by the lamellar contour and the points
where the double calcein labels joined, and the deepest
lamellae that followed the contour of the calcein label.
Rs.Ar was deﬁned as the space within the perimeter, Rs.Wi
as the distance between the endpoints, and Rs.De as the
largest distance at a 90-degree angle from the projected
bone surface to the cement line of the resorption cavity.
This Rs.De constituted the maximum ﬁnal depth of the
individual cavity (Fig. 1c). For each animal, between three
and ﬁve individual sites were analyzed. Parameters from
the multiple resorption cavities were averaged to obtain a
single value for each animal.
Variables were compared across groups by a one-way
analysis of variance (ANOVA) with signiﬁcance deﬁned as
P \ 0.05. Separate one-way ANOVAs were run for
VEH ? ALN groups and VEH ? RIS groups. When
ANOVA indicated signiﬁcant differences, post hoc analy
sis was performed by Fisher’s protected least signiﬁcant
difference (PLSD) test. Unpaired t-tests were used to assess
differences in the dose equivalents of RIS and ALN. All
data are presented as mean ± standard error.

Results
Treatment with ALN or RIS at doses consistent with those
used for treatment of postmenopausal osteoporosis signif
icantly reduced Rs.Ar by -31% (ALN) and -26% (RIS)
compared to VEH-treated animals (Fig. 2a). These doses
also signiﬁcantly reduced Rs.Wi (Fig. 2c) by -25% (ALN)
and -14% (RIS), but had no signiﬁcant effect on resorp
tion cavity depth: -14% (ALN) and -13% (RIS) com
pared to VEH-treated animals (Fig. 2b). There was no
signiﬁcant difference between dose equivalents of RIS and
ALN for any resorption cavity parameters.
At lower doses, neither RIS nor ALN signiﬁcantly
altered any parameter of BMU morphology. The highest
doses of both RIS and ALN produced changes in BMU
morphology similar to those of the osteoporosis-relevant
middle doses.

Fig. 2 Basic multicellular unit resorption parameters. a Resorption
area, b depth, and c width. Differences among groups were assessed
separately for control and alendronate groups and for control and
risedronate groups with post hoc tests within those groups when
appropriate (overall P \ 0.05). Data presented as mean ± standard
errors from 8–12 animals per group. P \ 0.05 vs. control (*) and low
dose within treatment (#). No differences were found between RIS
and ALN at equivalent doses, nor between the middle and high dose
within treatment groups

Discussion
BPs are widely used to treat metabolic bone diseases, the
most prominent of which is postmenopausal osteoporosis.
BPs exert their positive effects on the skeleton by sup
pressing the amount of bone remodeling [1, 2]. Clinically,

this remodeling suppression is assessed by serum/urine
biomarkers of collagen breakdown and in some cases
through the assessment of bone biopsy samples by histol
ogy. In histological analysis, the most prominent effect of
BPs is that they reduce the number of active BMUs. In
untreated individuals, there tends to be an imbalance
between resorption and formation in each BMU, such that
each BMU tends to have a net negative bone balance (less
bone is formed than is removed) [11, 12]. This, combined
with the more transient effect of the greater number of
resorption sites produced as a consequence of increased
activation frequency, leads to signiﬁcant bone loss in
osteoporosis. By lowering the number of active BMUs with
BP treatment, bone loss is slowed.
It has been suggested that in addition to reducing the
number of active BMUs, BPs affect the individual activity
of osteoclasts within a BMU. Speciﬁcally, studies have
assessed erosion depth, measured as the distance from the
cement line to the bone surface (or estimated bone surface)
of an individual BMU, which is indicative of osteoclast
activity within a given remodeling site. The results from
these analyses are equivocal, showing a tendency for BP
treatment to reduce Rs.De, but rarely reaching statistical
signiﬁcance [3, 5, 7–9, 13]. In the current study, we have
expanded the morphological assessment of individual
BMUs to include both Rs.Ar and Rs.Wi, in addition to the
more traditional measure of Rs.De. We show that BPs, at
doses equal to and above those used to treat postmeno
pausal osteoporosis result in smaller Rs.Ar and Rs.Wi of
individual BMUs with a nonsigniﬁcant trend toward lower
Rs.De. These results provide evidence that in addition to
the effect of suppressing the number of remodeling units,
BPs also reduce the amount of bone resorbed within each
BMU. Because Rs.De is not signiﬁcantly reduced, this is
likely caused not by the reduction in individual activity of
an osteoclast, but by fewer osteoclasts (perhaps due to
increased apoptosis) working within an individual BMU.
The implications of these data are signiﬁcant in that they
provide evidence of a second tissue-level mechanism—
reduced BMU resorption size—for reduced bone loss with
BPs. Of course, this would depend on formation at the
individual BMU level being unaffected with BPs. We have
previously shown, in these same specimens, that wall width
(a measure of osteoblast reﬁlling of remodeling sites) was
not altered by BPs [10].
Previous analyses on these same vertebrae have also
shown that these BP doses signiﬁcantly suppressed acti
vation frequency, the rate of new BMU initiation [10], and
that the effects were dose-dependent with RIS. In the
current work, we show that only the two higher doses of
each agent signiﬁcantly reduced BMU-level resorption
activity, with no difference between the two higher doses
of RIS. This leads us to speculate that these two effects of

BPs, suppression of the number of BMUs and osteoclast
activity within the BMU, are controlled independent of one
another, at least for RIS.
Several methods have been used to assess resorption
cavities morphology [3–6]. These techniques, which were
used on human biopsy and animal samples, are similar to
the current work in that the BMU is reconstructed by
making various assumptions about where the initial bone
surface was before resorption. One different aspect of the
current work is that we restricted our analysis to those
surfaces that were actively forming at the time of sacriﬁce
(deﬁned by the presence of calcein label). This was done
in order to assure that the BMUs we measured in the
treated animals were in fact active during the period of
treatment. If nonlabeled cavities were assessed, it would
not be possible to know that the BMU was formed in the
presence of BP treatment. As with the current work, most
of the previous methods suffer from the limitation of
trying to assess a three-dimensional structure (the BMU)
in two dimensions. This means that the area, width, and
depth we report may not directly correspond to a volu
metric measurement. One exception is where the remod
eling site was reconstructed in three dimensions. That
study found a signiﬁcant reduction in Rs.De with
3 months of RIS treatment (-25%) although it is not clear
whether these measures were restricted to those sites that
were remodeled during treatment [3]. Our Rs.De results
differ in that we did not show a signiﬁcant effect of BP
treatment, although the magnitude of difference between
control and treated animals was comparable (-15%).
What the current work shows, however, is that signiﬁcant
effects of BPs exist in other parameters, including Rs.Wi
and, most importantly, the resorption cavity area, which
previous methods have not assessed. On this basis, we
suggest that the assessment of additional parameters such
as Rs.Ar can provide important BMU-level information.
Ultimately, the development of three-dimensional methods
to assess the BMU are essential to advance our ability to
study how alterations in its morphology occur with disease
and treatment [14].
In conclusion, we show that reductions in resorption at
the BMU level likely contribute to the mechanism through
which BPs slow bone loss and that assessment of BMUlevel resorption is best done through comprehensive mea
sures of Rs.Ar, Rs.Wi, and Rs.De.
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